King Luther Capital Management Corp Makes New $4.19 Million Investment in Encompass Health Corporation $EHC

Posted by George Bondi on May 29th, 2026

King Luther Capital Management Corp bought a new position in Encompass Health Corporation (NYSE:EHC – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm bought 39,429 shares of the company’s stock, valued at approximately $4,185,000.

A number of other institutional investors have also bought and sold shares of the business. Thrivent Financial for Lutherans grew its stake in shares of Encompass Health by 57.8% in the 3rd quarter. Thrivent Financial for Lutherans now owns 1,194,859 shares of the company’s stock valued at $151,544,000 after buying an additional 437,464 shares during the period. AlphaCore Capital LLC purchased a new stake in shares of Encompass Health in the 4th quarter valued at approximately $4,881,000. Tudor Investment Corp ET AL grew its stake in shares of Encompass Health by 155.3% in the 3rd quarter. Tudor Investment Corp ET AL now owns 210,712 shares of the company’s stock valued at $26,765,000 after buying an additional 128,191 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Encompass Health by 5.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,410,335 shares of the company’s stock valued at $179,141,000 after buying an additional 70,387 shares during the period. Finally, AlphaQuest LLC grew its stake in shares of Encompass Health by 170.9% in the 3rd quarter. AlphaQuest LLC now owns 29,916 shares of the company’s stock valued at $3,800,000 after buying an additional 18,874 shares during the period. 97.25% of the stock is owned by hedge funds and other institutional investors.

Encompass Health Price Performance

Encompass Health stock opened at $105.45 on Friday. Encompass Health Corporation has a 1 year low of $92.77 and a 1 year high of $127.99. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.17 and a current ratio of 1.17. The company’s 50 day simple moving average is $103.18 and its 200-day simple moving average is $105.44. The company has a market capitalization of $10.46 billion, a price-to-earnings ratio of 17.61, a price-to-earnings-growth ratio of 2.27 and a beta of 0.72.

Encompass Health (NYSE:EHC – Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The company reported $1.60 earnings per share for the quarter, beating analysts’ consensus estimates of $1.51 by $0.09. Encompass Health had a return on equity of 18.28% and a net margin of 10.04%.The business had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.57 billion. During the same period in the previous year, the firm posted $1.37 earnings per share. The company’s revenue was up 9.0% on a year-over-year basis. Encompass Health has set its FY 2026 guidance at 5.890-6.110 EPS. As a group, equities research analysts expect that Encompass Health Corporation will post 5.96 earnings per share for the current year.

Encompass Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Wednesday, July 1st will be paid a $0.19 dividend. The ex-dividend date of this dividend is Wednesday, July 1st. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.7%. Encompass Health’s payout ratio is presently 12.69%.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Barclays decreased their price target on Encompass Health from $153.00 to $140.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 5th. Wall Street Zen raised Encompass Health from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. TD Cowen assumed coverage on Encompass Health in a research note on Thursday. They issued a “buy” rating and a $125.00 price target on the stock. Finally, Leerink Partners set a $152.00 price target on Encompass Health in a research note on Friday, May 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, Encompass Health has a consensus rating of “Buy” and an average price target of $142.75.

View Our Latest Report on EHC

Insiders Place Their Bets

In other news, EVP Patrick William Tuer sold 682 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $104.56, for a total value of $71,309.92. Following the completion of the transaction, the executive vice president owned 24,755 shares of the company’s stock, valued at approximately $2,588,382.80. This trade represents a 2.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Treasurer Edmund Fay sold 11,937 shares of the firm’s stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $107.00, for a total transaction of $1,277,259.00. Following the completion of the transaction, the treasurer directly owned 89,325 shares of the company’s stock, valued at approximately $9,557,775. The trade was a 11.79% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 1.80% of the company’s stock.

About Encompass Health

(Free Report)

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.